McDonald's Launching McValue Platform in US Restaurants in 2025
New, everyday value menu will be available nationwide starting
McValue will include current fan-favorites like the
"When it comes to value, we know there's no one-size-fits-all. We've worked closely with our franchisees to create a new platform that will let our customers define value on their own terms," said
Buy One, Add One for
Customers will be able to customize their own deals, mixing and matching their favorite items, thanks to the new Buy One, Add One for
McValue Breakfast Buy One, Add One for
- Sausage McMuffin®
- Sausage Biscuit
- Sausage Burrito
Hash Browns
McValue Lunch/Dinner Buy One, Add One for
- 6-pc. Chicken McNuggets®
- Double Cheeseburger
- McChicken®
- Small Fries
Drum roll please.... you heard it here first: our
There's no shortage of deals to be had at the Golden Arches. In partnership with franchisees in communities across the country,*** we will continue to offer local deals and in-App offers you can count on as well.
"As local small business owners, my fellow franchisees and I are always listening to what our customers want from their neighborhood McDonald's," said
So, get ready for a new year, new menu. Come
*Valid for item of equal or lesser value.
**Prices and participation may vary. McDouble® meal options may be priced at
***Local deals and offers will vary, as McDonald's franchisees are independent business owners who set their own pricing.
McDonald's USA
McDonald's USA, LLC, serves a variety of menu options made with quality ingredients to millions of customers every day. Ninety-five percent of McDonald's approximately 13,500
Contact: [email protected]
View original content to download multimedia:https://www.prnewswire.com/news-releases/mcdonalds-launching-mcvalue-platform-in-us-restaurants-in-2025-302313864.html
SOURCE McDonald's USA, LLC
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- 2026 World Robot Conference: Zoomlion Showcases Industrial Embodied Intelligence
- Implantica publishes Interim Report January - June 2026 (Q2)
- Akeso's AK157D1 (B7-H3 ADC) Cleared for Phase I Trial in Solid Tumors, Adding a Third Differentiated ADC to Its Pipeline
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share